Trial Profile
Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms MSD-GLP1
- 04 Dec 2012 Drug company changed from Merck Sharp and Dohme to Merck and Co as reported by ClinicalTrials.gov.
- 23 Sep 2008 New trial record.